罗莫佐单抗在意大利真实世界场景中治疗重度骨质疏松女性患者的早期经验:ROMEO研究
该回顾性分析纳入133例新接受罗莫佐单抗治疗的重度骨质疏松绝经后女性,观察骨密度替代阈值效应(BMD-STE)。所有部位骨密度较基线显著增加(均p<0.05),60%患者在12个月达到BMD-STE,且与双膦酸盐预暴露无关。
要点
- 罗莫佐单抗治疗后各部位骨密度较基线显著增加(均p<0.05)。
- 12个月时60%患者达到BMD-STE,与双膦酸盐预暴露无关。
- 6个月时56.4%患者达到所有骨折最小风险降低的STE。
核心结论
- 罗莫佐单抗带来的骨密度快速增加支持其用于降低重度骨质疏松绝经后女性的骨折风险, regardless of prior bisphosphonate exposure.
研究设计与样本
- 回顾性分析,纳入2022年11月29日至2024年7月1日(数据提取日)新接受罗莫佐单抗治疗的重度骨质疏松绝经后女性。
- 共纳入133例重度骨质疏松绝经后女性,平均年龄72.5±9.5岁,最低T值-3.3±0.87;70例随访至第6个月,41例随访至第12个月。
主要发现
- 所有部位骨密度较基线显著增加(均p<0.05)。
- 第6个月时,56.4%患者达到所有骨折最小风险降低的STE。
- 基线腰椎T值≤-2.5的患者中,第6个月和第12个月分别有18.2%和32.0%达到T值目标(>-2.5)。
- P1nP水平在第3个月和第6个月显著升高,CTX水平显著降低(均p<0.05 vs. 基线)。
关键数值与推荐
- 12个月时60%患者达到BMD-STE,无论是否既往使用双膦酸盐。
- 基线腰椎T值≤-2.5的患者中,第6个月18.2%、第12个月32.0%达到T值目标(>-2.5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The impact of romosozumab on the bone mineral density surrogate threshold effect (BMD-STE) in postmenopausal women with severe osteoporosis is unknown. Significant BMD gains with romosozumab were observed and 60% of patients achieved the BMD-STE at month 12, regardless of bisphosphonate pre-exposure. Romosozumab offers effective treatment in high-risk fracture patients. PURPOSE: A real-life study to investigate the impact of romosozumab on the bone mineral density surrogate threshold effect (BMD-STE) for minimal fracture risk reduction. METHODS: A retrospective analysis of postmenopausal women with severe osteoporosis newly treated with romosozumab from 29 November 2022 until 01 July 2024 (extraction date). BMD of the lumbar spine (L1-L4), femoral neck, and total hip was assessed at baseline and months 6 and 12, and the BMD-STE was evaluated. Blood serum samples were assayed for bone turnover markers and calcium-phosphate metabolism. Subgroup analyses compared patients minimally exposed to bisphosphonates with patients pre-exposed to bisphosphonates. Patients contributed to the analysis according to their observation period. RESULTS: Overall, 133 postmenopausal women with severe osteoporosis newly treated with romosozumab were included (mean age 72.5 ± 9.5 years, lowest T score -3.3 ± 0.87); 70 patients were followed up to month 6, and 41 patients up to month 12. Significant increases in BMD were observed at all sites (all p < 0.05 vs. baseline). At month 6, 56.4% of patients reached the STE for minimal fracture risk reduction for all fractures. Among patients with a lumbar spine T-score ≤ -2.5 at baseline, 18.2% and 32.0% reached the T-score target (> -2.5) at months 6 and 12, respectively. P1nP levels increased significantly and CTX levels decreased significantly at months 3 and 6, (all p < 0.05 vs. baseline). CONCLUSION: The rapid increase in BMD with romosozumab supports its use for reducing fracture risk in postmenopausal women with severe osteoporosis, regardless of prior bisphosphonate exposure.
引用
- Adami G, Bartezaghi M, Montanari F, et al. ROMosozumab early experience in female patients with severe osteoporosis in an Italian real-world setting, the ROMEO study. Osteoporos Int. 2025. PMID: 41081804. doi:10.1007/s00198-025-07722-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。